FI81264B - Mikropartiklar och gasblaosor innehaollande ultraljudkontrastmedel. - Google Patents
Mikropartiklar och gasblaosor innehaollande ultraljudkontrastmedel. Download PDFInfo
- Publication number
- FI81264B FI81264B FI841462A FI841462A FI81264B FI 81264 B FI81264 B FI 81264B FI 841462 A FI841462 A FI 841462A FI 841462 A FI841462 A FI 841462A FI 81264 B FI81264 B FI 81264B
- Authority
- FI
- Finland
- Prior art keywords
- microparticles
- agent according
- solid
- galactose
- sucrose
- Prior art date
Links
- 239000011859 microparticle Substances 0.000 claims abstract description 94
- 239000007788 liquid Substances 0.000 claims abstract description 33
- 239000007787 solid Substances 0.000 claims abstract description 26
- 239000002872 contrast media Substances 0.000 claims abstract description 15
- 239000004094 surface-active agent Substances 0.000 claims abstract description 12
- 239000002245 particle Substances 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 239000002961 echo contrast media Substances 0.000 claims description 25
- 229930182830 galactose Natural products 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- -1 polyoxyethylene Polymers 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 20
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 12
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 12
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 12
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 12
- 239000000194 fatty acid Substances 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 claims description 4
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 4
- XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 claims description 4
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 4
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 229940035023 sucrose monostearate Drugs 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- FOLJTMYCYXSPFQ-CJKAUBRRSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-(octadecanoyloxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl octadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)O[C@@H]1O[C@@]1(COC(=O)CCCCCCCCCCCCCCCCC)[C@@H](O)[C@H](O)[C@@H](CO)O1 FOLJTMYCYXSPFQ-CJKAUBRRSA-N 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 229910052751 metal Chemical class 0.000 claims description 2
- 239000002184 metal Chemical class 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims 2
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 239000008151 electrolyte solution Substances 0.000 claims 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000000575 pesticide Substances 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 150000004043 trisaccharides Chemical class 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 abstract description 10
- 238000002360 preparation method Methods 0.000 description 32
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 31
- 238000009826 distribution Methods 0.000 description 22
- 239000000725 suspension Substances 0.000 description 22
- 210000002216 heart Anatomy 0.000 description 17
- 235000002639 sodium chloride Nutrition 0.000 description 14
- 239000008215 water for injection Substances 0.000 description 11
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 238000002592 echocardiography Methods 0.000 description 6
- 229960001375 lactose Drugs 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000001632 homeopathic effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000003445 sucroses Chemical class 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Polymers OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
- ZPVGIKNDGJGLCO-VGAMQAOUSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZPVGIKNDGJGLCO-VGAMQAOUSA-N 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000013155 cardiography Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- UMWKZHPREXJQGR-UHFFFAOYSA-N n-methyl-n-(2,3,4,5,6-pentahydroxyhexyl)decanamide Chemical compound CCCCCCCCCC(=O)N(C)CC(O)C(O)C(O)C(O)CO UMWKZHPREXJQGR-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940032085 sucrose monolaurate Drugs 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3925—Markers, e.g. radio-opaque or breast lesions markers ultrasonic
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Radiology & Medical Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acoustics & Sound (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Fire-Detection Mechanisms (AREA)
- Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Claims (15)
1. Kontrastmedel innehällande mikropartiklar och gasbläsor för ultraljuddiagnostik, kännetecknat 5 därav, att det innehäller 0,01-10 vikt-% mikropartiklar av ett fast, gränsytaktivt ämne, eventuellt i kombination med mikropartiklar av ett icke-gränsytaktivt fast ämne i ett vätskeformigt bärarematerial.
2. Medel enligt patentkravet 1, känneteck-10 n a t därav, att det som fast gränsytaktivt ämne inne- häller lecitin, polyoxietylenfettsyraester, glycerinpoly-etylenglykolricinoleat, kolesterol, polyoxietylenpolyoxi-propylenpolymerer, sackarosester, xyloglycerid, mättade eller omättade (C4-C20)-fettalkoholer, mättade eller omät-15 tade (C4-C20)-fettsyror eller metallsalter därav, polyoxi-etylenfettsyraestrar, mono-, di- och triglycerider eller fettsyraestrar som mikropartiklar.
3. Medel enligt patentkraven 1 eller 2, kännetecknat därav, att det innehäller magnesiumstearat, 20 askorbylpalmitat, sackarosmonopalmitat, sackarosmono- stearat eller sackarosdistearat som fast gränsytaktivt ämne i form av mikropartiklar i en koncentration av 0,01-5 vikt-%, företrädesvis 0,04-1 vikt-%.
4. Medel enligt patentkravet 1, känneteck-25 n a t därav, att det som eventuellt närvarande mikropar- tiklarna ett icke-gränsytaktivt fast ämne innehäller cyk-lodextrin, monosackarid, disackarid, trisackarid, polyoler eller oorganiska eller organiska salter med en koncentration av 5-50 vikt-%.
5. Medel enligt patentkraven 1 eller 4, känne tecknat därav, att det som eventuellt närvarande icke-gränsytaktivt fast material innehäller galaktos, lak-tos eller α-cyklodextrin som mikropartiklar i en koncentration av 5-50 vikt-%, företrädesvis 9-40 vikt-%. 35 li 23 81 264
6. Medel enligt patentkravet 1, känneteck-n a t därav, att det som fysiologiskt godtagbar bärarema-terial innehäller vatten, fysiologisk elektrolytlösning, en vattenlösning av en- eller flervärda alkoholer säsom 5 glycerin, polyetylenglykol eller propylenglykolmetylester eller en vattenlösning av en mono- eller disackarid.
7. Medel enligt patentkraven 1 eller 6, k ä n n e -t e c k n a t därav, att det som fysiologiskt godtagbart vätskeformigt bärarematerial innehäller vatten, fysiolo- 10 gisk koksaltlösning, 10 %:ig, vattenlösning av laktos eller 20 %:ig vattenlösning av galaktos.
8. Medel enligt patentkravet 1, känneteck-n a t därav, att det innehäller mikropartiklar av magne-siumstearat och galaktos i en 20 %:ig vattenlösning galak- 15 tos.
9. Medel enligt patentkravet 1, känneteck-n a t därav, att det innehäller mikropartiklar av askorb-ylpalmitat och galaktos i vatten.
10. Medel enligt patentkravet 1, känneteck- 20. a t därav, att det innehäller mikropartiklar av askorb- ylpalmitat och α-cyklodextrin i en fysiologisk koksaltlösning.
11. Medel enligt patentkravet 1, känneteck-n a t därav, att det innehäller mikropartiklar av askorb- 25 ylpalmitat i en 10 %:ig vattenlösning av laktos.
12. Medel enligt patentkravet 1, känneteck-n a t därav, att det innehäller mikropartiklar av sacka-rosmonopalmitat och galaktos i vatten.
13. Medel enligt patentkravet 1, känneteck- 30. a t därav, att det innehäller mikropartiklar av sacka- rosmonostearat och galaktos i vatten.
14. Medel enligt patentkravet 1, känneteck-n a t därav, att det innehäller mikropartiklar av sacka-rosdistearat och galaktos i vatten. 35
15. Förpackning för framställning av ett ultraljud- 24 81 264 kontrastmedel innehällande mikropartiklar och gasbläsor, kännetecknad därav, att den omfattar a) en behällare, som har en volym av 5-10 ml och som är försedd md ett tillslutningsorgan, vllken möjllggör 5 uttagnlng av innehället under sterila förhällanden, och vilken behällare Sr fylld med 4 ml en vätskeformig bärare, och b) en andra behällare, som har en volym av 5-10 ml och som är försedd med ett tillslutningsorgan, vilken möj- 10 liggör uttagning av innehället eller tillförsel av en äm-nesblandning under sterila förhällande, och vilken behäl-lare är fylld med mikropartiklat av ett fast, gränsytak-tivt ämne, eventuellt i kombination med mikropartiklar av ett icke-gränsytaktivt fast ämne med en medelpartikelstor-15 lek av <1-10 pm, varvid det gränsytaktivt ämnets viktför-hällande tili det eventuellt närvarande icke-gränsytaktiva fasta ämnet är 0,01-5:100 och mängden mikropartiklar är 5-50 vikt-%, företrädesvis 9-40 vikt-%. li
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3313946 | 1983-04-15 | ||
| DE3313946A DE3313946A1 (de) | 1983-04-15 | 1983-04-15 | Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI841462A0 FI841462A0 (fi) | 1984-04-12 |
| FI841462A FI841462A (fi) | 1984-10-16 |
| FI81264B true FI81264B (fi) | 1990-06-29 |
| FI81264C FI81264C (sv) | 1990-10-10 |
Family
ID=6196665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI841462A FI81264C (sv) | 1983-04-15 | 1984-04-12 | Mikropartiklar och gasblåsor innehållande ultraljudkontrastmedel |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP0122624B1 (sv) |
| JP (1) | JPS59205328A (sv) |
| AT (1) | ATE36958T1 (sv) |
| AU (1) | AU566928B2 (sv) |
| CA (1) | CA1239092A (sv) |
| DE (2) | DE3313946A1 (sv) |
| DK (1) | DK165171C (sv) |
| FI (1) | FI81264C (sv) |
| IE (1) | IE57272B1 (sv) |
| NO (1) | NO161356C (sv) |
| NZ (1) | NZ207853A (sv) |
| ZA (1) | ZA842801B (sv) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3313947A1 (de) * | 1983-04-15 | 1984-10-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel |
| DE3834705A1 (de) | 1988-10-07 | 1990-04-12 | Schering Ag | Ultraschallkontrastmittel aus gasblaeschen und fettsaeure enthaltenden mikropartikeln |
| US5141738A (en) * | 1983-04-15 | 1992-08-25 | Schering Aktiengesellschaft | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof |
| DK151366C (da) * | 1984-12-05 | 1988-05-16 | Tytex As | Trusse samt fremgangsmaade til fremstilling heraf |
| DE3637926C1 (de) * | 1986-11-05 | 1987-11-26 | Schering Ag | Ultraschall-Manometrieverfahren in einer Fluessigkeit mittels Mikroblaeschen |
| DE3741201A1 (de) * | 1987-12-02 | 1989-06-15 | Schering Ag | Ultraschallarbeitsverfahren und mittel zu dessen durchfuehrung |
| DE3741199A1 (de) * | 1987-12-02 | 1989-08-17 | Schering Ag | Verwendung von ultraschallkontrastmitteln fuer die ultraschall-lithotripsie |
| DE3803971C2 (de) * | 1988-02-05 | 1997-09-18 | Schering Ag | Ultraschallkontrastmittel |
| US5425366A (en) * | 1988-02-05 | 1995-06-20 | Schering Aktiengesellschaft | Ultrasonic contrast agents for color Doppler imaging |
| DE3803972A1 (de) * | 1988-02-05 | 1989-08-10 | Schering Ag | Ultraschallkontrastmittel |
| EP0586875A1 (de) * | 1988-02-05 | 1994-03-16 | Schering Aktiengesellschaft | Ultraschallkontrastmittel, Verfahren zu deren Herstellung und deren Verwendung als Diagnostika und Therapeutika |
| US5922304A (en) * | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
| IN172208B (sv) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
| USRE39146E1 (en) | 1990-04-02 | 2006-06-27 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
| US7083778B2 (en) | 1991-05-03 | 2006-08-01 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| US6613306B1 (en) | 1990-04-02 | 2003-09-02 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| US6989141B2 (en) | 1990-05-18 | 2006-01-24 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| US5445813A (en) | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
| US5578292A (en) | 1991-11-20 | 1996-11-26 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
| US5137928A (en) * | 1990-04-26 | 1992-08-11 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
| US5205287A (en) * | 1990-04-26 | 1993-04-27 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
| US5190982A (en) * | 1990-04-26 | 1993-03-02 | Hoechst Aktiengesellschaft | Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents |
| AU636481B2 (en) * | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
| US5147631A (en) * | 1991-04-30 | 1992-09-15 | Du Pont Merck Pharmaceutical Company | Porous inorganic ultrasound contrast agents |
| ATE151992T1 (de) † | 1991-06-03 | 1997-05-15 | Nycomed Imaging As | Verbesserungen im bezug auf kontrastmittel |
| EP0593627A1 (en) * | 1991-07-05 | 1994-04-27 | The University Of Rochester | Ultrasmall non-aggregated porous particles entrapping gas-bubbles |
| AU675050B2 (en) * | 1991-07-05 | 1997-01-23 | Nycomed Imaging As | Improvements in or relating to contrast agents |
| JPH0521183U (ja) * | 1991-09-02 | 1993-03-19 | サンデン株式会社 | 回転斜板式圧縮機 |
| GB9200388D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
| GB9200391D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
| GB9200387D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
| IL104084A (en) | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them |
| PL182223B1 (pl) | 1993-12-15 | 2001-11-30 | Bracco Research Sa | Biokompatybilna faza rozproszona do otrzymywania srodka kontrastowego do badan ultradzwiekowych, srodek kontrastowy do badan ultradzwiekowych, suchy preparat srodka kontrastowego oraz dwuskladnikowy zestaw do otrzymywania srodka kontrastowego do badan ultradzwiekowych PL PL PL |
| DE4406474A1 (de) * | 1994-02-23 | 1995-08-24 | Schering Ag | Gas enthaltende Mikropartikel, diese enthaltende Mittel, deren Verwendung in der Ultraschalldiagnostik, sowie Verfahren zur Herstellung der Partikel und Mittel |
| DE19510690A1 (de) | 1995-03-14 | 1996-09-19 | Schering Ag | Polymere Nano- und/oder Mikropartikel, Verfahren zu deren Herstellung, sowie Verwendung in medizinischen Diagnostik und Therapie |
| DE19543077C2 (de) * | 1995-11-13 | 1997-10-16 | Schering Ag | Verwendung von gashaltigen Metallkomplexen als Ultraschallkontrastmittel |
| DE19602930A1 (de) * | 1996-01-18 | 1997-07-24 | Schering Ag | Poröse Matrices aus niedermolekularen Substanzen zur Genierung stabiler Gasblasensuspensionen, deren Verwendung als Ultraschallkontrastmittel sowie Verfahren zu deren Herstellung |
| DE19813174A1 (de) * | 1998-03-25 | 1999-05-27 | Schering Ag | Mikropartikel aus Polymeren und mindestens einer gerüstbildenden Komponente und ihre Herstellung und Verwendung in der Ultraschalldiagnostik und zur ultraschallinduzierten Wirkstofffreisetzung |
| AU1705300A (en) | 1998-10-12 | 2000-05-01 | Mallinckrodt, Inc. | Novel ultrasound contrast agents |
| US6254852B1 (en) | 1999-07-16 | 2001-07-03 | Dupont Pharmaceuticals Company | Porous inorganic targeted ultrasound contrast agents |
| AU2001266696A1 (en) | 2000-06-02 | 2001-12-11 | Bracco Research Usa | Compounds for targeting endothelial cells |
| DE60223239T2 (de) | 2001-04-06 | 2008-08-14 | Bracco Research S.A. | Vorrichtung zur Messung lokaler physikalischer Parameter in einem flüssigkeitsgefüllten Hohlraum |
| AU2002359576A1 (en) | 2001-12-03 | 2003-06-17 | Ekos Corporation | Catheter with multiple ultrasound radiating members |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| CA2513044A1 (en) | 2002-03-01 | 2004-08-05 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
| US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
| CA2477836A1 (en) | 2002-03-01 | 2003-09-12 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
| US7462366B2 (en) | 2002-03-29 | 2008-12-09 | Boston Scientific Scimed, Inc. | Drug delivery particle |
| US7842377B2 (en) | 2003-08-08 | 2010-11-30 | Boston Scientific Scimed, Inc. | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient |
| US8012454B2 (en) | 2002-08-30 | 2011-09-06 | Boston Scientific Scimed, Inc. | Embolization |
| US7883490B2 (en) | 2002-10-23 | 2011-02-08 | Boston Scientific Scimed, Inc. | Mixing and delivery of therapeutic compositions |
| PL1944312T3 (pl) | 2003-03-03 | 2012-12-31 | Dyax Corp | Peptydy, które specyficznie wiążą receptor HGF (CMET) i ich zastosowanie |
| US7976823B2 (en) | 2003-08-29 | 2011-07-12 | Boston Scientific Scimed, Inc. | Ferromagnetic particles and methods |
| US7901770B2 (en) | 2003-11-04 | 2011-03-08 | Boston Scientific Scimed, Inc. | Embolic compositions |
| US7736671B2 (en) | 2004-03-02 | 2010-06-15 | Boston Scientific Scimed, Inc. | Embolization |
| US8173176B2 (en) | 2004-03-30 | 2012-05-08 | Boston Scientific Scimed, Inc. | Embolization |
| US7311861B2 (en) | 2004-06-01 | 2007-12-25 | Boston Scientific Scimed, Inc. | Embolization |
| US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
| US8425550B2 (en) | 2004-12-01 | 2013-04-23 | Boston Scientific Scimed, Inc. | Embolic coils |
| US7858183B2 (en) | 2005-03-02 | 2010-12-28 | Boston Scientific Scimed, Inc. | Particles |
| US7727555B2 (en) | 2005-03-02 | 2010-06-01 | Boston Scientific Scimed, Inc. | Particles |
| US7963287B2 (en) | 2005-04-28 | 2011-06-21 | Boston Scientific Scimed, Inc. | Tissue-treatment methods |
| US9463426B2 (en) | 2005-06-24 | 2016-10-11 | Boston Scientific Scimed, Inc. | Methods and systems for coating particles |
| US8518069B2 (en) | 2005-09-07 | 2013-08-27 | Cabochon Aesthetics, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
| US10548659B2 (en) | 2006-01-17 | 2020-02-04 | Ulthera, Inc. | High pressure pre-burst for improved fluid delivery |
| US7967763B2 (en) | 2005-09-07 | 2011-06-28 | Cabochon Aesthetics, Inc. | Method for treating subcutaneous tissues |
| US9486274B2 (en) | 2005-09-07 | 2016-11-08 | Ulthera, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
| US9358033B2 (en) | 2005-09-07 | 2016-06-07 | Ulthera, Inc. | Fluid-jet dissection system and method for reducing the appearance of cellulite |
| US9011473B2 (en) | 2005-09-07 | 2015-04-21 | Ulthera, Inc. | Dissection handpiece and method for reducing the appearance of cellulite |
| US8007509B2 (en) | 2005-10-12 | 2011-08-30 | Boston Scientific Scimed, Inc. | Coil assemblies, components and methods |
| US8101197B2 (en) | 2005-12-19 | 2012-01-24 | Stryker Corporation | Forming coils |
| US8152839B2 (en) | 2005-12-19 | 2012-04-10 | Boston Scientific Scimed, Inc. | Embolic coils |
| US7947368B2 (en) | 2005-12-21 | 2011-05-24 | Boston Scientific Scimed, Inc. | Block copolymer particles |
| US8414927B2 (en) | 2006-11-03 | 2013-04-09 | Boston Scientific Scimed, Inc. | Cross-linked polymer particles |
| US10182833B2 (en) | 2007-01-08 | 2019-01-22 | Ekos Corporation | Power parameters for ultrasonic catheter |
| PL2170181T3 (pl) | 2007-06-22 | 2014-08-29 | Ekos Corp | Sposób i aparat do leczenia wylewów wewnątrzczaszkowych |
| US8439940B2 (en) | 2010-12-22 | 2013-05-14 | Cabochon Aesthetics, Inc. | Dissection handpiece with aspiration means for reducing the appearance of cellulite |
| US11096708B2 (en) | 2009-08-07 | 2021-08-24 | Ulthera, Inc. | Devices and methods for performing subcutaneous surgery |
| US9358064B2 (en) | 2009-08-07 | 2016-06-07 | Ulthera, Inc. | Handpiece and methods for performing subcutaneous surgery |
| US20150343079A1 (en) | 2012-10-25 | 2015-12-03 | Sogang University Research Foundation | Ultrasound contrast agent with nanoparticles including drug and method for preparing the same |
| KR101595795B1 (ko) | 2014-03-19 | 2016-02-22 | (주)아이엠지티 | 약물을 함유한 나노입자가 결합된 이중-목적 paｔ／초음파 조영제 및 이의 제조방법 |
| CN107708581B (zh) | 2015-06-10 | 2021-11-19 | Ekos公司 | 超声波导管 |
| CA3104889A1 (en) | 2018-07-23 | 2020-01-30 | Nutragenom, Llc | Composition and methods for generating and sustaining molecular hydrogen (h2) in aqueous systems |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4277367A (en) * | 1978-10-23 | 1981-07-07 | Wisconsin Alumni Research Foundation | Phantom material and method |
| US4265251A (en) * | 1979-06-28 | 1981-05-05 | Rasor Associates, Inc. | Method of determining pressure within liquid containing vessel |
| WO1982001642A1 (en) * | 1980-11-17 | 1982-05-27 | Med Inc Ultra | Microbubble precursors and methods for their production and use |
| DE3141641A1 (de) * | 1981-10-16 | 1983-04-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Ultraschall-kontrastmittel und dessen herstellung |
-
1983
- 1983-04-15 DE DE3313946A patent/DE3313946A1/de not_active Withdrawn
-
1984
- 1984-02-20 DK DK078984A patent/DK165171C/da not_active IP Right Cessation
- 1984-04-05 IE IE835/84A patent/IE57272B1/en not_active IP Right Cessation
- 1984-04-11 CA CA000451730A patent/CA1239092A/en not_active Expired
- 1984-04-12 JP JP59071939A patent/JPS59205328A/ja active Granted
- 1984-04-12 FI FI841462A patent/FI81264C/sv not_active IP Right Cessation
- 1984-04-13 DE DE8484104210T patent/DE3473828D1/de not_active Expired
- 1984-04-13 NZ NZ207853A patent/NZ207853A/en unknown
- 1984-04-13 NO NO841489A patent/NO161356C/no not_active IP Right Cessation
- 1984-04-13 EP EP84104210A patent/EP0122624B1/de not_active Expired
- 1984-04-13 AT AT84104210T patent/ATE36958T1/de not_active IP Right Cessation
- 1984-04-13 AU AU26805/84A patent/AU566928B2/en not_active Ceased
- 1984-04-13 ZA ZA842801A patent/ZA842801B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0122624B1 (de) | 1988-09-07 |
| EP0122624A3 (en) | 1986-11-20 |
| NO161356C (no) | 1989-08-09 |
| IE57272B1 (en) | 1992-07-01 |
| DK165171B (da) | 1992-10-19 |
| IE840835L (en) | 1984-10-15 |
| DE3313946A1 (de) | 1984-10-18 |
| FI841462A0 (fi) | 1984-04-12 |
| AU2680584A (en) | 1984-10-18 |
| AU566928B2 (en) | 1987-11-05 |
| JPH0425934B2 (sv) | 1992-05-06 |
| DK165171C (da) | 1993-03-01 |
| ZA842801B (en) | 1984-11-28 |
| CA1239092A (en) | 1988-07-12 |
| EP0122624A2 (de) | 1984-10-24 |
| FI81264C (sv) | 1990-10-10 |
| ATE36958T1 (de) | 1988-09-15 |
| DK78984A (da) | 1984-10-16 |
| NZ207853A (en) | 1988-01-08 |
| NO841489L (no) | 1984-10-16 |
| JPS59205328A (ja) | 1984-11-20 |
| DE3473828D1 (en) | 1988-10-13 |
| FI841462A (fi) | 1984-10-16 |
| NO161356B (no) | 1989-05-02 |
| DK78984D0 (da) | 1984-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI81264B (fi) | Mikropartiklar och gasblaosor innehaollande ultraljudkontrastmedel. | |
| FI81265C (sv) | Mikropartiklar och gasblåsor innehållande ultraljudkontrastmedel | |
| CA1338507C (en) | Ultrasonic contrast medium made up of small gas bubbles and fatty-acid-containing microparticles | |
| FI81008B (fi) | Flytande blandning foer mottagning och stabilisering av gasbubblor foer anvaendning som kontrastmedel vid ultraljuddiagnostik. | |
| US5141738A (en) | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof | |
| JPH11506960A (ja) | 超音波造影に使用するための核形成及び活性化方法 | |
| JP4242448B2 (ja) | ガスを含む微細粒子、微細粒子を含む薬剤、超音波診断における薬剤の使用並びに粒子及び薬剤の製造方法 | |
| REISNER et al. | RICHARD S. MELTZER, ANTONIO F. AMICO |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: SCHERING AKTIENGESELLSCHAFT |